3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
19
Lung Neoplasms
10
Stomach Neoplasms
8
Neoplasm Metastasis
6
Colorectal Neoplasms
6
Breast Neoplasms
6
Nasopharyngeal Carcinoma
5
Leukemia, Myeloid, Acute
5
Esophageal Neoplasms
5
Small Cell Lung Carcinoma
4
Pancreatic Neoplasms
4
Neoplasms
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Ovarian Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Endometrial Neoplasms
3
Adenocarcinoma Of Esophagus
3
Urinary Bladder Neoplasms
2
Rectal Neoplasms
2
Mouth Neoplasms
2
Lymphoma
2
Head and Neck Neoplasms
2
Glioma
2
Glioblastoma
2
Carcinoma, Squamous Cell
2
Anatomic Stage II Breast Cancer AJCC v8
2
Advanced Solid Tumors
2
Unresectable Locally Recurrent Rectal Cancer
1
Thymoma
1
Interventions
Oxaliplatin
9
Capecitabine
9
Fluorouracil
7
pembrolizumab
6
Paclitaxel
6
Leucovorin
6
Cisplatin
5
zolbetuximab
4
trastuzumab deruxtecan
3
enzalutamide
3
durvalumab
3
cemiplimab
3
Trastuzumab
3
Gemcitabine
3
Docetaxel
3
fludarabine
2
darolutamide
2
Taxes
2
Ramucirumab
2
Radiotherapy, Image-Guided
2
Radiosurgery
2
Pemetrexed
2
Nivolumab
2
Irinotecan
2
Cyclophosphamide
2
Carboplatin
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
vistusertib
1
tucatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
Drug Therapy
×
90 days
×
Clear all
NCT06504615
2026-04-03
METAGIO
Bristol-Myers Squibb
Active not recruiting
208 enrolled